English

MERRIMACK PHARMACEUTICALS INC

EDGAR

MACK Quarterly report (10-Q) · filed 2024-05-15

57 filing records in this dataset, filed from 2011-07-08 to 2024-05-15. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

61.2 million USD

2016 Q4 · USD

Exact inputs and evidence

Revenue: 144273000 USD Source
Revenue: 83033000 USD Source

Operating margin

-67.82%

2016 Q4 · %

Exact inputs and evidence

Operating Income: -147327000 USD Source
Operating Income: -105791000 USD Source
Revenue: 144273000 USD Source
Revenue: 83033000 USD Source

Operating cash flow

-30.9 million USD

2016 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -170241000 USD Source
Operating Cash Flow: -139344000 USD Source

Cash and cash equivalents: 234 million USD 2024-03-31 Source
Exact value

234160000 USD
Long-term debt including current maturities: 15 million USD 2019-03-31 Source
Exact value

15000000 USD
Shares outstanding: 14.5 million shares 2024-03-31 Source
Exact value

14532000 shares

Reported share-count change

1.94% · 277 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

14255000 shares · 2023-03-31· Source
14532000 shares · 2024-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

144 million USD

2016-01-01 – 2016-12-31

Exact inputs and evidence

Revenue: 21281000 USD · 2016-01-01 – 2016-03-31 Source
Revenue: 33681000 USD · 2016-04-01 – 2016-06-30 Source
Revenue: 28071000 USD · 2016-07-01 – 2016-09-30 Source
Revenue: 144273000 USD · 2016-01-01 – 2016-12-31 Source
Revenue: 83033000 USD · 2016-01-01 – 2016-09-30 Source

Net income

-3.05 million USD

2020-01-01 – 2020-12-31

Exact inputs and evidence

Net income: 249000 USD · 2020-01-01 – 2020-03-31 Source
Net income: -1163000 USD · 2020-04-01 – 2020-06-30 Source
Net income: -1006000 USD · 2020-07-01 – 2020-09-30 Source
Net income: -3028000 USD · 2020-01-01 – 2020-12-31 Source
Net income: -1900000 USD · 2020-01-01 – 2020-09-30 Source

Operating cash flow

-2.44 million USD

2023-04-01 – 2024-03-31

Exact inputs and evidence

Operating cash flow: -1000000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -356000 USD · 2023-01-01 – 2023-03-31 Source
Operating cash flow: -1200000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -1000000 USD · 2023-01-01 – 2023-06-30 Source
Operating cash flow: -1500000 USD · 2023-01-01 – 2023-12-31 Source
Operating cash flow: -1200000 USD · 2023-01-01 – 2023-09-30 Source
Operating cash flow: -1300000 USD · 2024-01-01 – 2024-03-31 Source

Capital expenditure

118 thousand USD

2018-01-01 – 2018-12-31

Exact inputs and evidence

Capital expenditure: 16000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 118000 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 16000 USD · 2018-01-01 – 2018-03-31 Source
Capital expenditure: 118000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 118000 USD · 2018-01-01 – 2018-06-30 Source
Capital expenditure: 118000 USD · 2018-01-01 – 2018-12-31 Source
Capital expenditure: 118000 USD · 2018-01-01 – 2018-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2024-05-15.

Financial data available through: 2023-12-31.

Coverage by financial measure

Revenue: 4 of 11 periods available· newest 2016-12-31
Operating income: 11 of 11 periods available· newest 2023-12-31
Net income: 8 of 11 periods available· newest 2020-12-31
Operating cash flow: 11 of 11 periods available· newest 2023-12-31
Capital expenditure: 6 of 11 periods available· newest 2018-12-31
Total assets: 11 of 11 periods available· newest 2023-12-31
Total liabilities: 11 of 11 periods available· newest 2023-12-31
Current assets: 11 of 11 periods available· newest 2023-12-31
Current liabilities: 11 of 11 periods available· newest 2023-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2023-12-31
Long-term debt including current maturities: 1 of 11 periods available· newest 2018-12-31
Shares outstanding: 11 of 11 periods available· newest 2023-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Operating cash flow
+USD 242,000

Prior period

−USD 1.74 million

2022-01-01 – 2022-12-31
Current period

−USD 1.5 million

2023-01-01 – 2023-12-31

Exact inputs and evidence

-1500000 − -1742000 = 242000 USD

-1742000 USD · 2022-01-01 – 2022-12-31
Inspect prior input Prior source
-1500000 USD · 2023-01-01 – 2023-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · MERRIMACK PHARMACEUTICALS INC · 2023-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Year-over-year change in Operating cash flow: 242000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -1500000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000095017024027966/mack-20231231.htm#791338 Filing: 000095017024027966 Input fundies:OperatingCashFlow: -1742000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000095017024027966/mack-20231231.htm#728752 Filing: 000095017024027966
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Net income, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2016 2016-01-01 – 2016-12-31

Revenue USD 144.27 million 100% of revenue
Cost of revenue USD 6.91 million 4.8% of revenue
Operating expenses USD 190.29 million 132% of revenue
Other operating costs Derived USD 94.39 million 65% of revenue
Operating income −USD 147.33 million −102% of revenue
Tax, interest and other Derived USD 4.41 million 3.1% of revenue
Net income −USD 151.74 million −105% of revenue

Cash

Operating cash flow −USD 170.24 million −118% of revenue
Capital expenditure USD 2.64 million 1.8% of revenue
Free cash flow Derived −USD 172.88 million −120% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 Operating loss: operating costs were 164% of revenue.
2015 Operating loss: operating costs were 263% of revenue.
2016 Operating loss: operating costs were 202% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	102756000	169012000 Derived	-66256000	17035000 Derived	-83291000	-40843000 Derived	Source 2014-01-01 – 2014-12-31: 102756000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -66256000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -83291000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -34808000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 6035000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	89258000	234339000 Derived	-145081000	2876000 Derived	-147957000	-117258000 Derived	Source 2015-01-01 – 2015-12-31: 89258000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -145081000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -147957000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -105356000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 11902000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	144273000	291600000 Derived	-147327000	4413000 Derived	-151740000	-172881000 Derived	Source 2016-01-01 – 2016-12-31: 144273000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -147327000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -151740000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -170241000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 2640000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 144.3M 2016

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Revenue	47786000	Revenue: 47786000 Open source
20142014-12-31	Revenue	102756000	Revenue: 102756000 Open source
20152015-12-31	Revenue	89258000	Revenue: 89258000 Open source
20162016-12-31	Revenue	144273000	Revenue: 144273000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

61.6% 2016

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Year over year	No prior comparable period	Revenue: 47786000 Open source
20142014-12-31	Year over year	115%	Revenue: 102756000 Open source Revenue: 47786000 Open source
20152015-12-31	Year over year	-13.1%	Revenue: 89258000 Open source Revenue: 102756000 Open source
20162016-12-31	Year over year	61.6%	Revenue: 144273000 Open source Revenue: 89258000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -102.1% 2016

Net margin -105.2% 2016

Free cash flow margin -119.8% 2016

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Operating margin	-252.2%	Operating Income: -120540000 Open source Revenue: 47786000 Open source
20142014-12-31	Operating margin	-64.5%	Operating Income: -66256000 Open source Revenue: 102756000 Open source
20152015-12-31	Operating margin	-162.5%	Operating Income: -145081000 Open source Revenue: 89258000 Open source
20162016-12-31	Operating margin	-102.1%	Operating Income: -147327000 Open source Revenue: 144273000 Open source
20132013-12-31	Net margin	-274%	Net Income: -130925000 Open source Revenue: 47786000 Open source
20142014-12-31	Net margin	-81.1%	Net Income: -83291000 Open source Revenue: 102756000 Open source
20152015-12-31	Net margin	-165.8%	Net Income: -147957000 Open source Revenue: 89258000 Open source
20162016-12-31	Net margin	-105.2%	Net Income: -151740000 Open source Revenue: 144273000 Open source
20132013-12-31	Free cash flow margin	Not reported	Revenue: 47786000 Open source
20142014-12-31	Free cash flow margin	-39.7%	Revenue: 102756000 Open source Operating Cash Flow: -34808000 Open source Capital Expenditure: 6035000 Open source
20152015-12-31	Free cash flow margin	-131.4%	Revenue: 89258000 Open source Operating Cash Flow: -105356000 Open source Capital Expenditure: 11902000 Open source
20162016-12-31	Free cash flow margin	-119.8%	Revenue: 144273000 Open source Operating Cash Flow: -170241000 Open source Capital Expenditure: 2640000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -170.2M 2016

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Operating cash flow	Not reported	No source recorded
20142014-12-31	Operating cash flow	-34808000	Operating Cash Flow: -34808000 Open source
20152015-12-31	Operating cash flow	-105356000	Operating Cash Flow: -105356000 Open source
20162016-12-31	Operating cash flow	-170241000	Operating Cash Flow: -170241000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -172.9M 2016

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20132013-12-31	Free cash flow	Unavailable	No source recorded
20142014-12-31	Free cash flow	-40843000	Operating Cash Flow: -34808000 Open source Capital Expenditure: 6035000 Open source
20152015-12-31	Free cash flow	-117258000	Operating Cash Flow: -105356000 Open source Capital Expenditure: 11902000 Open source
20162016-12-31	Free cash flow	-172881000	Operating Cash Flow: -170241000 Open source Capital Expenditure: 2640000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

410.1% 2016

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Liabilities / assets	122.4%	Total Liabilities: 235545000 Open source Total Assets: 192417000 Open source
20142014-12-31	Liabilities / assets	164.4%	Total Liabilities: 260577000 Open source Total Assets: 158506000 Open source
20152015-12-31	Liabilities / assets	178.2%	Total Liabilities: 418569000 Open source Total Assets: 234880000 Open source
20162016-12-31	Liabilities / assets	410.1%	Total Liabilities: 334142000 Open source Total Assets: 81483000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.65× 2016

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Current assets / current liabilities	2.89×	Current Assets: 166644000 Open source Current Liabilities: 57734000 Open source
20142014-12-31	Current assets / current liabilities	1.19×	Current Assets: 132065000 Open source Current Liabilities: 111111000 Open source
20152015-12-31	Current assets / current liabilities	1.94×	Current Assets: 201394000 Open source Current Liabilities: 103746000 Open source
20162016-12-31	Current assets / current liabilities	0.65×	Current Assets: 57435000 Open source Current Liabilities: 88222000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 83.29 million Exact value Exact value: -83291000 USD 2014-01-01 – 2014-12-31: -83291000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MERRIMACK PHARMACEUTICALS INC · 2014-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Net Income: -83291000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -83291000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459017003026/mack-20161231.xml#222812 Filing: 000156459017003026 The citation records this snapshot. The page link may show a newer release later.	−USD 34.81 million Exact value Exact value: -34808000 USD 2014-01-01 – 2014-12-31: -34808000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MERRIMACK PHARMACEUTICALS INC · 2014-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Operating Cash Flow: -34808000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -34808000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459017003026/mack-20161231.xml#253420 Filing: 000156459017003026 The citation records this snapshot. The page link may show a newer release later.	USD 6.04 million Exact value Exact value: 6035000 USD 2014-01-01 – 2014-12-31: 6035000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MERRIMACK PHARMACEUTICALS INC · 2014-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Capital Expenditure: 6035000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 6035000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459017003026/mack-20161231.xml#255172 Filing: 000156459017003026 The citation records this snapshot. The page link may show a newer release later.	−USD 40.84 million Calculation and evidence -34808000 − 6035000 USD Exact free cash flow: -40843000 USD 2014-01-01 – 2014-12-31: -34808000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 6035000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MERRIMACK PHARMACEUTICALS INC · 2014-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Free cash flow: -40843000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -34808000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459017003026/mack-20161231.xml#253420 Filing: 000156459017003026 Input fundies:CapitalExpenditure: 6035000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459017003026/mack-20161231.xml#255172 Filing: 000156459017003026 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 147.96 million Exact value Exact value: -147957000 USD 2015-01-01 – 2015-12-31: -147957000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MERRIMACK PHARMACEUTICALS INC · 2015-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Net Income: -147957000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -147957000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-20171231.xml#179489 Filing: 000156459018005246 The citation records this snapshot. The page link may show a newer release later.	−USD 105.36 million Exact value Exact value: -105356000 USD 2015-01-01 – 2015-12-31: -105356000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MERRIMACK PHARMACEUTICALS INC · 2015-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Operating Cash Flow: -105356000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -105356000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-20171231.xml#215114 Filing: 000156459018005246 The citation records this snapshot. The page link may show a newer release later.	USD 11.9 million Exact value Exact value: 11902000 USD 2015-01-01 – 2015-12-31: 11902000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MERRIMACK PHARMACEUTICALS INC · 2015-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Capital Expenditure: 11902000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11902000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-20171231.xml#216397 Filing: 000156459018005246 The citation records this snapshot. The page link may show a newer release later.	−USD 117.26 million Calculation and evidence -105356000 − 11902000 USD Exact free cash flow: -117258000 USD 2015-01-01 – 2015-12-31: -105356000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 11902000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MERRIMACK PHARMACEUTICALS INC · 2015-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Free cash flow: -117258000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -105356000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-20171231.xml#215114 Filing: 000156459018005246 Input fundies:CapitalExpenditure: 11902000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-20171231.xml#216397 Filing: 000156459018005246 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 151.74 million Exact value Exact value: -151740000 USD 2016-01-01 – 2016-12-31: -151740000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MERRIMACK PHARMACEUTICALS INC · 2016-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Net Income: -151740000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -151740000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-20171231.xml#179334 Filing: 000156459018005246 The citation records this snapshot. The page link may show a newer release later.	−USD 170.24 million Exact value Exact value: -170241000 USD 2016-01-01 – 2016-12-31: -170241000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MERRIMACK PHARMACEUTICALS INC · 2016-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Operating Cash Flow: -170241000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -170241000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-20171231.xml#214901 Filing: 000156459018005246 The citation records this snapshot. The page link may show a newer release later.	USD 2.64 million Exact value Exact value: 2640000 USD 2016-01-01 – 2016-12-31: 2640000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MERRIMACK PHARMACEUTICALS INC · 2016-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Capital Expenditure: 2640000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2640000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-20171231.xml#216187 Filing: 000156459018005246 The citation records this snapshot. The page link may show a newer release later.	−USD 172.88 million Calculation and evidence -170241000 − 2640000 USD Exact free cash flow: -172881000 USD 2016-01-01 – 2016-12-31: -170241000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 2640000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MERRIMACK PHARMACEUTICALS INC · 2016-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Free cash flow: -172881000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -170241000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-20171231.xml#214901 Filing: 000156459018005246 Input fundies:CapitalExpenditure: 2640000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459018005246/mack-20171231.xml#216187 Filing: 000156459018005246 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	USD 472.03 million Exact value Exact value: 472028000 USD 2017-01-01 – 2017-12-31: 472028000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MERRIMACK PHARMACEUTICALS INC · 2017-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Net Income: 472028000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: 472028000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459019006385/mack-20181231.xml#127395 Filing: 000156459019006385 The citation records this snapshot. The page link may show a newer release later.	−USD 125.81 million Exact value Exact value: -125811000 USD 2017-01-01 – 2017-12-31: -125811000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MERRIMACK PHARMACEUTICALS INC · 2017-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Operating Cash Flow: -125811000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -125811000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459019006385/mack-20181231.xml#146938 Filing: 000156459019006385 The citation records this snapshot. The page link may show a newer release later.	USD 915,000 Exact value Exact value: 915000 USD 2017-01-01 – 2017-12-31: 915000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MERRIMACK PHARMACEUTICALS INC · 2017-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Capital Expenditure: 915000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 915000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459019006385/mack-20181231.xml#147787 Filing: 000156459019006385 The citation records this snapshot. The page link may show a newer release later.	−USD 126.73 million Calculation and evidence -125811000 − 915000 USD Exact free cash flow: -126726000 USD 2017-01-01 – 2017-12-31: -125811000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 915000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MERRIMACK PHARMACEUTICALS INC · 2017-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Free cash flow: -126726000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -125811000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459019006385/mack-20181231.xml#146938 Filing: 000156459019006385 Input fundies:CapitalExpenditure: 915000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459019006385/mack-20181231.xml#147787 Filing: 000156459019006385 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 40.51 million Exact value Exact value: -40506000 USD 2018-01-01 – 2018-12-31: -40506000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MERRIMACK PHARMACEUTICALS INC · 2018-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Net Income: -40506000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -40506000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459020010531/mack-20191231.xml#117009 Filing: 000156459020010531 The citation records this snapshot. The page link may show a newer release later.	−USD 65.59 million Exact value Exact value: -65588000 USD 2018-01-01 – 2018-12-31: -65588000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MERRIMACK PHARMACEUTICALS INC · 2018-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Operating Cash Flow: -65588000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -65588000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459020010531/mack-20191231.xml#133344 Filing: 000156459020010531 The citation records this snapshot. The page link may show a newer release later.	USD 118,000 Exact value Exact value: 118000 USD 2018-01-01 – 2018-12-31: 118000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MERRIMACK PHARMACEUTICALS INC · 2018-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Capital Expenditure: 118000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 118000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459020010531/mack-20191231.xml#134208 Filing: 000156459020010531 The citation records this snapshot. The page link may show a newer release later.	−USD 65.71 million Calculation and evidence -65588000 − 118000 USD Exact free cash flow: -65706000 USD 2018-01-01 – 2018-12-31: -65588000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 118000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MERRIMACK PHARMACEUTICALS INC · 2018-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Free cash flow: -65706000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -65588000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459020010531/mack-20191231.xml#133344 Filing: 000156459020010531 Input fundies:CapitalExpenditure: 118000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459020010531/mack-20191231.xml#134208 Filing: 000156459020010531 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 17.33 million Exact value Exact value: -17332000 USD 2019-01-01 – 2019-12-31: -17332000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MERRIMACK PHARMACEUTICALS INC · 2019-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Net Income: -17332000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -17332000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459021012087/mack-10k_20201231.htm#859400 Filing: 000156459021012087 The citation records this snapshot. The page link may show a newer release later.	−USD 31.37 million Exact value Exact value: -31368000 USD 2019-01-01 – 2019-12-31: -31368000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MERRIMACK PHARMACEUTICALS INC · 2019-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Operating Cash Flow: -31368000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -31368000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459021012087/mack-10k_20201231.htm#1107719 Filing: 000156459021012087 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 3.03 million Exact value Exact value: -3028000 USD 2020-01-01 – 2020-12-31: -3028000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MERRIMACK PHARMACEUTICALS INC · 2020-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Net Income: -3028000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3028000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459021012087/mack-10k_20201231.htm#857445 Filing: 000156459021012087 The citation records this snapshot. The page link may show a newer release later.	−USD 4.63 million Exact value Exact value: -4625000 USD 2020-01-01 – 2020-12-31: -4625000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MERRIMACK PHARMACEUTICALS INC · 2020-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Operating Cash Flow: -4625000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -4625000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000156459022009320/mack-10k_20211231.htm#784158 Filing: 000156459022009320 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	Unavailable Not reported for this period.	−USD 218,000 Exact value Exact value: -218000 USD 2021-01-01 – 2021-12-31: -218000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MERRIMACK PHARMACEUTICALS INC · 2021-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Operating Cash Flow: -218000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -218000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000095017023007063/mack-20221231.htm#966054 Filing: 000095017023007063 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	Unavailable Not reported for this period.	−USD 1.74 million Exact value Exact value: -1742000 USD 2022-01-01 – 2022-12-31: -1742000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MERRIMACK PHARMACEUTICALS INC · 2022-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Operating Cash Flow: -1742000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1742000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000095017024027966/mack-20231231.htm#728752 Filing: 000095017024027966 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	Unavailable Not reported for this period.	−USD 1.5 million Exact value Exact value: -1500000 USD 2023-01-01 – 2023-12-31: -1500000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MERRIMACK PHARMACEUTICALS INC · 2023-12-31 MERRIMACK PHARMACEUTICALS INC (edgar:1274792) Operating Cash Flow: -1500000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T18:39:58Z Snapshot: 05fe8ed5993586e4973cb2c340da4a27dc8f85153c46fb40dc919a272360ae08 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1274792/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1500000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1274792/000095017024027966/mack-20231231.htm#791338 Filing: 000095017024027966 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

57 filings · 2,914 latest values · 2,914 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001274792, 1274792, MACK, edgar:1274792

Also known as MERRIMACK PHARMACEUTICALS INC, MERRIMACK PHARMACEUTICALS, INC.

MERRIMACK PHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Operating cash flow

Where revenue goes

2016 2016-01-01 – 2016-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation